Limited coverage drugs – cysteamine ophthalmic solution

Publication date: February 28, 2022

Generic name

cysteamine ophthalmic solution

Strength

0.37 %/w/w (3.8 mg/mL)

Form

ophthalmic viscous solution

Special Authority criteria

Approval period

For the treatment of corneal cystine crystal deposits in patients with cystinosis, also known as ocular cystinosis.

The patient must be under the care of an ophthalmologist experienced in the management of the ocular manifestations of cystinosis.

1 year

Practitioner exemptions

  • None

Special notes

  • None

Special Authority request form(s)